Research activity information

• Paquinimod Targeting of the S100A8/A9 Axis Suppresses Liver Metastasis in Aged Mice.

  Takao Tsuneki, Masafumi Saito, Kimihiro Yamashita, Masayuki Ando, Keisuke Yasuda, Naoto Shirakami, Ryota Ito, Yukari Adachi, Hiroki Kagiyama, Takaaki Tachibana, Masaki Imai, Sachiko Inubushi, Kazuki Kanayama, Yu-Ichiro Koma, Mitsugu Fujita, Joerg-Matthias Pollok, Yutaka Sugita, Taro Ikeda, Yasufumi Koterazawa, Tomoaki Aoki, Hitoshi Harada, Yasunori Otowa, Naoki Urakawa, Hironobu Goto, Hiroshi Hasegawa, Shingo Kanaji, Takeru Matsuda, Yoshihiro Kakeji

  Background: Aging profoundly alters host immunity, yet how age-associated immune changes in the liver influence the growth of metastatic tumors remains incompletely understood. Liver metastasis is a major cause of cancer-related mortality, particularly in elderly patients, for whom aggressive treatments are often not feasible. This study aimed to clarify how aging reshapes the hepatic immune microenvironment and to identify age-associated host factors that influence liver metastasis growth. Methods: Tumor-naïve and tumor-bearing young and aged mice were analyzed using a syngeneic MC38 liver metastasis model. Immune cell composition in the liver was assessed by flow cytometry, and gene expression was evaluated by quantitative reverse transcription PCR (RT-qPCR). Public transcriptomic datasets were screened to identify age-associated inflammatory factors. The functional relevance of the S100A8/A9 axis was examined using the small-molecule inhibitor paquinimod. Results: Aging was associated with a distinct baseline immune cell composition in the liver. During liver metastasis, overall growth was comparable between young and aged mice; however, metastatic lesions in aged hosts showed increased expression of multiple inflammation-related genes and prominent accumulation of Ly6G+ cells. In silico screening identified S100a9 as one of the most highly upregulated inflammation-related genes in aged livers, which was confirmed in both tumor-naïve and metastatic liver tissues. Pharmacological modulation of the S100A8/A9 axis with paquinimod significantly reduced liver metastasis growth in aged, but not young, mice, and was accompanied by a shift in immune cell composition, including an increased representation of CD8+ T cells. Conclusions: These findings indicate that aging is associated with a distinct hepatic immune context that shapes the inflammatory and cellular composition of the tumor microenvironment during liver metastasis. S100A9 emerges as a key age-associated, host-derived factor that is functionally relevant to the growth of liver metastases in aged hosts, supporting the S100A8/A9 axis as a context-specific therapeutic target.

  May 2026, Cancers, 18(10) (10), English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Serum Extracellular Vesicles Double-positive for CD9 and CD147 or for CD9 and CD63 Decrease After Surgical Resection in Patients With Colorectal Cancer: Potential Biomarkers of Residual Tumor.

  Yukari Adachi, Takeru Matsuda, Sachiko Inubushi, Keisuke Yasuda, Ryota Ito, Naoto Shirakami, Takaaki Tachibana, Masaki Imai, Hiroki Kagiyama, Takao Tsuneki, Masayuki Ando, Masafumi Saito, Yutaka Sugita, Taro Ikeda, Yasufumi Koterazawa, Tomoaki Aoki, Hitoshi Harada, Yasunori Otowa, Naoki Urakawa, Hironobu Goto, Hiroshi Hasegawa, Shingo Kanaji, Kimihiro Yamashita, Robert M Hoffman, Yoshihiro Kakeji

  BACKGROUND/AIM: Extracellular vesicles (EVs), including exosomes, are abundant in body fluids, and EV surface proteins can be profiled as potential minimally invasive biomarkers. CD147 (EMMPRIN/Basigin) is a tumor-associated surface glycoprotein implicated in cancer progression. CD9 and CD63 are tetraspanin membrane proteins widely used as EV markers. The present study aimed to evaluate the clinical significance of serum EV subsets double-positive for CD9 and CD63, or for CD9 and CD147 in patients with colorectal cancer (CRC) before and after tumor resection. MATERIALS AND METHODS: Sixteen patients with CRC were recruited, and paired pre- and postoperative serum samples were analyzed for CD9+ CD63+ EVs and CD9+ CD147+ EVs. Serum EVs were quantified using the ExoCounter system with antibody-conjugated beads. CD147 expression in resected tumor tissue was analyzed by immunohistochemistry. RESULTS: CD9+ CD63+ EVs were significantly reduced in postoperative samples compared with preoperative samples (p=0.0151). CD9+ CD147+ EVs also showed a significant postoperative decrease (p=0.0186). CD147 immunostaining was positive in 13 out of 16 resected tumors (81.3%). In patients with CD147 negative tumors (n=3), serum CD9+ CD147+ EV levels were low at both pre- and postoperative time points and remained unchanged. CONCLUSION: Serum CD9+ CD63+ and CD9+ CD147+ EV subsets decreased after CRC surgery, supporting their potential utility as minimally invasive liquid biopsy biomarkers of postoperative tumor burden. Future prospective clinical trials will determine whether these EV subsets are indeed biomarkers of postoperative residual tumor.

  May 2026, Anticancer research, 46(5) (5), 2345 - 2352, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Hospital variation in surgical outcomes for gastric cancer: the impact of case-mix and treatment across a global cohort.

  Sander J M van Hootegem, Margrietha van der Linde, Marcel A Schneider, Jeesun Kim, Felix Berlth, Yutaka Sugita, Peter P Grimminger, Gian Luca Baiocchi, Giovanni De Manzoni, Maria Bencivenga, Suzanne S Gisbertz, Souya Nunobe, Han-Kwang Yang, Christian A Gutschow, Sjoerd M Lagarde, Hester F Lingsma, Bas P L Wijnhoven

  BACKGROUND: There is substantial global variation in demographics, disease burden, and treatment for gastric cancer patients. Benchmarking is an instrument to assess such variation and enables to investigate to which extent case-mix and treatments explain differences in outcomes. We aimed to evaluate hospital-level variation in surgical outcomes following gastrectomy for gastric cancer before and after adjusting for case-mix and treatment-related factors. METHODS: Data were retrieved from the GastroBenchmark and GASTRODATA databases, including consecutive gastric cancer resections performed between 2017 and 2021 from 43 centers. Patients who underwent a (sub)total gastrectomy for adenocarcinoma were identified. Outcomes included 30-day mortality, severe complications (Clavien-Dindo grade ≥ 3a), > 15 lymph nodes retrieved, negative resection margin (R0), prolonged hospitalization (> 14 days), readmissions (< 30 days), reoperations, and escalation of care. We assessed absolute inter-hospital variation for outcomes, and estimated outcomes using mixed-effect logistic regression models with a random intercept. We estimated crude, case-mix adjusted, and case-mix and treatment adjusted hospital effects. The conditional and marginal pseudo-R2 were used to quantify the variance in outcome explained by case-mix and treatment-related factors. RESULTS: A total of 7818 patients from 41 hospitals were included, with contributions ranging from 12 to 2554 patients per hospital (IQR: 49-146). Observed 30-day mortality and severe complications ranged from 0 to 9.7% (IQR: 3.2%) and 5.3 to 31% (IQR: 7.7%), respectively. Larger variation between hospitals was observed for retrieval of > 15 lymph nodes (IQR: 12.3%), prolonged hospitalization (IQR: 14.4%) and readmissions (IQR 11.3%). This variation was reduced in the crude model, while adjusting for case-mix and treatment-related factors did not significantly reduce variation for any outcome. Case-mix factors had a limited contribution to the explained variance, except for 30-day mortality (33.9%) and negative resection margins (31.7%). Adding treatment-related factors increased the explained variance for 30-day mortality by 40.8%, but had low impact (< 10%) on the variance in most surgical outcomes. CONCLUSIONS: Case-mix and treatment factors are not the primary drivers of variation in surgical outcomes following gastrectomy. Case-mix adjustment can improve the validity of global comparisons for 30-day mortality, but does not seem essential for comparing other investigated outcomes.

  Jan. 2026, Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, English, Domestic magazine

  Scientific journal


• Hepatic Fibrosis Predicts Poor Response to Preoperative Chemotherapy, Postoperative Malnutrition, and Poor Survival in Patients with Esophageal Squamous Cell Carcinoma Undergoing Minimally Invasive Esophagectomy: A Retrospective Analysis.

  Yasufumi Koterazawa, Hironobu Goto, Tomoaki Aoki, Masayuki Ando, Yutaka Sugita, Taro Ikeda, Hitoshi Harada, Yasunori Otowa, Naoki Urakawa, Hiroshi Hasegawa, Shingo Kanaji, Kimihiro Yamashita, Takeru Matsuda, Yoshihiro Kakeji

  BACKGROUND: Esophageal squamous cell carcinoma (ESCC) and hepatic cirrhosis (HC) share major risk factors, including alcohol consumption and smoking. Consequently, patients with HC exhibit an elevated incidence of ESCC. Although HC is widely recognized to contribute to poor prognosis following esophagectomy for ESCC, the underlying mechanisms remain poorly understood. This study aimed to investigate the association between hepatic fibrosis evaluated using the fibrosis-4 (FIB-4) index and postoperative outcomes among patients with ESCC undergoing esophagectomy. METHODS: We retrospectively analyzed 461 patients with ESCC who underwent minimally invasive esophagectomy at Kobe University Hospital. Hepatic fibrosis was evaluated using the FIB-4 index, which estimates liver fibrosis based on routine blood test parameters. Patients were stratified into two groups: fibrosis-positive (FIB-4 > 2.67) and fibrosis-negative (FIB-4 ≤ 2.67). RESULTS: Among patients with cT1 tumors, overall survival (OS) did not differ significantly between the two groups. However, among those with ≥cT2 tumors, the fibrosis-positive group showed significantly worse OS than the fibrosis-negative group (P = 0.0148). Additionally, the fibrosis-positive group had a significantly higher incidence of poor response to preoperative chemotherapy (P = 0.0075). Postoperative serum albumin levels were markedly lower at 3, 6, and 12 months in the fibrosis-positive group (P = 0.015, 0.043, and 0.0066, respectively). While albumin levels recovered to baseline in the fibrosis-negative group within 12 months, no such recovery was observed in the fibrosis-positive group. CONCLUSIONS: Preoperative hepatic fibrosis is associated with poor response to preoperative chemotherapy and prolonged postoperative malnutrition, contributing to poorer long-term survival outcomes among patients with ESCC undergoing minimally invasive esophagectomy.

  Jan. 2026, Annals of surgical oncology, 33(1) (1), 444 - 452, English, International magazine

  Scientific journal


• Optimal Cutoff Size of Large Borrmann Type III Gastric Cancer: Is 8 cm Accurate in Predicting Survival and Incidence of Peritoneal Metastasis?

  Yutaka Sugita, Manabu Ohashi, Naoki Miyazaki, Motonari Ri, Rie Makuuchi, Tomoyuki Irino, Masaru Hayami, Takeshi Sano, Souya Nunobe

  BACKGROUND: Large type III gastric cancer (GC) ≥ 8 cm has conventionally been categorized with type IV GC in Japan, leading to alternative treatment strategies such as neoadjuvant chemotherapy and staging laparoscopy (SL). However, whether 8 cm is the correct cutoff remains unclear. METHODS: We retrospectively analyzed patients clinically diagnosed with advanced GC who underwent surgery at our department. Patients were classified by Borrmann type, and clinicopathological characteristics including survival outcomes and peritoneal metastasis incidence were analyzed based on tumor size to determine the optimal cutoff for large type III GC. RESULTS: Tumor size correlated with overall survival in type III GC. Although hazard ratios (HRs) for "large" and "small" type III vs. type IV remained comparable up to the 8 cm cutoff (0.60 and 0.41, respectively), HR for "large" type III GC increases sharply to 0.74 with a 10 cm cutoff. Subgroup analysis based on histological subtype revealed similar results in the undifferentiated type. Conversely, a larger cutoff value appeared more appropriate for the differentiated type. The largest difference in the incidence of peritoneal metastasis was observed with a 6 cm cutoff (36.1% in "large" type III and 10.2% in "small" type III), and similar results were observed in the undifferentiated type at the same cutoff. CONCLUSIONS: In terms of survival, a 10 cm cutoff may more accurately define large type III GC than the conventional 8 cm. However, if surgeons intend to identify peritoneal metastasis by SL, type III GC ≥ 6 cm could be a possible candidate.

  Jan. 2026, Annals of gastroenterological surgery, 10(1) (1), 77 - 86, English, Domestic magazine

  Scientific journal


• Feasibility of Minimally Invasive Surgery for Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy: A Four-arm Comparative Study.

  Taro Ikeda, Shingo Kanaji, Naoki Urakawa, Hitoshi Harada, Yutaka Sugita, Masayuki Ando, Yasufumi Koterazawa, Tomoaki Aoki, Yasunori Otowa, Hironobu Goto, Hiroshi Hasegawa, Kimihiro Yamashita, Takeru Matsuda, Yoshihiro Kakeji

  BACKGROUND/AIM: Previous studies demonstrated the safety of laparoscopic gastrectomy in patients with locally advanced gastric cancer. However, the feasibility of minimally invasive surgery (MIS) following neoadjuvant chemotherapy (NAC) for locally advanced gastric cancer remains unclear. To our knowledge, no previous study has conducted a comprehensive analysis that evaluated NAC and surgical approach simultaneously. This study aimed to assess the feasibility of MIS for locally advanced gastric cancer after NAC using a four-arm comparison. PATIENTS AND METHODS: This study retrospectively analyzed 174 patients who underwent gastrectomy at Kobe University Hospital between January 2011 and July 2024. The patients were categorized into four groups based on NAC and surgical approaches: No NAC/open surgery (n=63), no NAC/MIS (n=49), NAC/open surgery (n=20), and NAC/MIS (n=42). We compared surgical and survival outcomes among the four groups. RESULTS: Patients in the group treated with NAC/MIS experienced less blood loss, fewer transfusions, and a shorter hospital stay. Additionally, compared with the NAC/open (20%) and no NAC/MIS (6.1%) groups, the rate of severe postoperative complications (grade ≥III) was lowest in the group treated with NAC/MIS, with no incidence of pancreatic fistula. The R0 resection rate was highest (97.6%) in the group treated with NAC/MIS. Although 5-year relapse-free survival and overall survival were higher in the group treated with NAC/MIS, the differences were not statistically significant. CONCLUSION: This four-arm study suggests that minimally invasive surgery after NAC for locally advanced gastric cancer may be technically and oncologically safe.

  Dec. 2025, Anticancer research, 45(12) (12), 5557 - 5566, English, International magazine

  Scientific journal


• Standardization using soft coagulation scissors and Maryland bipolar forceps techniques reduces the operative time and incidence of recurrent laryngeal nerve palsy in robot-assisted minimally invasive esophagectomy.

  Hironobu Goto, Yasufumi Koterazawa, Tomoaki Aoki, Yutaka Sugita, Taro Ikeda, Hitoshi Harada, Yasunori Otowa, Naoki Urakawa, Hiroshi Hasegawa, Shingo Kanaji, Takeru Matsuda, Taro Oshikiri, Yoshihiro Kakeji

  PURPOSE: Minimally invasive esophagectomy (MIE) is the standard surgical procedure. Robot-assisted MIE (RAMIE) was developed to overcome the problems associated with conventional MIE. This study investigated whether or not standardizing surgical procedures for RAMIE using soft coagulation scissors and Maryland bipolar forceps could improve short-term outcomes. METHODS: This study included 130 patients who underwent RAMIE. Clinicopathological characteristics and surgical outcomes were compared before and after standardization by two expert surgeons as well as between the standardized and trainee groups. A cumulative sum control chart (CUSUM) was used to evaluate changes in operative time. RESULTS: The console time during the thoracic procedure was shorter in the standardized group than in the pre-standardized group (P < 0.001). The rate of recurrent laryngeal nerve palsy was lower in the standardized group than in the pre-standardized group (P = 0.039). No significant differences were observed between the standardized and trainee groups. In the standardized and trainee groups, CUSUM clearly indicated that the console time peak occurred in the 12th and 16th cases. CONCLUSIONS: Standardization of surgical procedures using an appropriate device for each surgical step could improve surgical outcomes in RAMIE. Furthermore, it may facilitate safer and more efficient surgical training.

  Nov. 2025, Surgery today, English, Domestic magazine

  Scientific journal


• Provision of additional oral nutritional supplements to postgastrectomy patients based on regular diet intake to meet their energy requirements reduces body weight loss.

  Hitoshi Harada, Shingo Kanaji, Moe Tsuboi, Saki Nakatani, Satoko Tabuchi, Ikuko Yamamoto, Yutaka Sugita, Taro Ikeda, Yasufumi Koterazawa, Tomoaki Aoki, Yasunori Otowa, Naoki Urakawa, Hironobu Goto, Hiroshi Hasegawa, Kimihiro Yamashita, Takeru Matsuda, Michiko Takahashi, Yoshihiro Kakeji

  BACKGROUND & AIMS: Oral nutritional supplements (ONS) administered after gastrectomies can prevent postoperative weight loss. However, the amount of additional energy to be added to energy requirements after gastrectomy is unclear. This study aimed to clarify dietary energy intake and its association with weight loss in postgastrectomy patients. METHODS: We performed a single-center, single-arm, open-label, non-randomized clinical trial. Fifty patients with gastric cancer who underwent distal or total gastrectomy were included in this study. Until 3 months postoperatively, the patients continuously consumed ONS and their intake was recorded. Additionally, the patients took photos of their regular diets. Hospital visits were made every 2 weeks to investigate calorie intake (from regular diet plus ONS), physical findings, and nutritional status. The primary endpoint was the percentage of body weight loss (%BWL) at 3 months after gastrectomy. RESULTS: Data were available for 45 patients. %BWL was 7.5 ± 5.1 % at 3 months postoperatively. The group with ONS intake <200 kcal/day tended to show a lower %BWL; however, this was not significant. No correlation was observed between ONS and regular dietary calorie intake. The required calorie intake was 1588 ± 157 kcal/day. Calorie intake from regular diet alone and from regular diet plus ONS were 1330 ± 280 and 1487 ± 300 kcal/day, respectively. The sufficient group, whose total calorie intake met the requirements, had significantly reduced body weight loss, compared with the insufficient group. CONCLUSIONS: After gastrectomy, regular diet alone often fails to meet nutritional requirements, and ONS supplementation may reduce %BWL at 3 months postoperatively by correcting energy deficits. This study was registered with the University Hospital Medical Information Network Clinical Trial Registry (UMIN-CTR; UMIN000047451; https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000054111).

  Oct. 2025, Clinical nutrition ESPEN, 69, 449 - 457, English, International magazine

  Scientific journal


• Impact of postoperative complications on clinical outcomes after gastrectomy for cancer: multicentre study

  Sander J M van Hootegem, Margrietha van der Linde, Marcel A Schneider, Jeesun Kim, Felix Berlth, Yutaka Sugita, Peter P Grimminger, Gian Luca Baiocchi, Giovanni De Manzoni, Maria Bencivenga, Suzanne Gisbertz, Souya Nunobe, Han-Kwang Yang, Christian A Gutschow, Sjoerd M Lagarde, Hester F Lingsma, Bas P L Wijnhoven, Hidde Overtoom, Ines Gockel, René Thieme, Ewen A Griffiths, William Butterworth, Henrik Nienhüser, Beat Müller, Nerma Crnovrsanin, Felix Nickel, Suzanne S Gisbertz, Mark I van Berge Henegouwen, Philip H Pucher, Kashuf Khan, Asif Chaudry, Pranav H Patel, Manuel Pera, Mariagiulia Dal Cero, Carlos Garcia, Guillermo Martinez Salinas, Paulo Kassab, Osvaldo Antônio Prado Castro, Enrique Norero, Paul Wisniowski, Luke Randall Putnam, Pietro Maria Lombardi, Giovanni Ferrari, Rita Gudaityte, Almantas Maleckas, Leanne Prodehl, Antonio Castaldi, Michel Prudhomme, Simone Giacopuzzi, Riccardo Rosati, Francesco Puccetti, Domenico D’Ugo, Daniel Gero, Hyuk-Joon Lee, Guillaume Piessen, Justine Lerooy, Johanna Wilhelmina van Sandick, Suzanne S Gisbertz, Mark I van Berge Henegouwen, Jessie Elliott, Paolo Morgagni, Arnulf H Hölscher, Martin Hemmerich, Stefan Mönig, Mickael Chevallay, Piotr Kołodziejczyk, Henk Hartgrink, Paulo Matos da Costa, Filipe Castro Borges, Andrew Davies, Cara Baker, William Allum, Sacheen Kumar, Wojciech Polkowski, Karol Rawicz-Pruszyński, Uberto Fumagalli Romario, Stefano De Pascale, Antonio Tarasconi, Daniel Reim, Ilaria Pergolini, Lucio Lara Santos, Pedro Carvalho Martins, Alberto Biondi, Riccardo Rosati, Maurizio Degiuli, Rossella Reddavid, Wojciech Kielan, Paul Magnus Schneider, Thomas Murphy

  Abstract Background To reduce the clinical and economic burden of complications after gastrectomy for gastric cancer, specific complications should be targeted to effectively allocate healthcare resources for quality improvement and preventive measures. The aim of this study was to assess the impact of complications on clinical outcomes. Methods This was a retrospective multicentre study of patients who underwent (sub)total gastrectomy for gastric or junctional adenocarcinoma at 43 centres in 16 countries between 2017 and 2021. Outcomes were escalation of care, reoperation, prolonged hospital stay (greater than the 75th percentile), readmission, and 30-day mortality. Adjusted relative risks and population attributable fractions were estimated for specific complication–outcome pairs. The population attributable fraction represents the percentage reduction in the frequency of an adverse outcome if a complication could be completely prevented in the population. Results In total, 7829 patients were included. Postoperative complications occurred in 1884 patients (24.1%). The most frequent complications were pulmonary complications (436 patients (5.6%)), anastomotic leakage (363 patients (4.6%)), and abdominal collection (301 patients (3.8%)). Anastomotic leakage, cardiac complications, and pulmonary complications had the greatest impact on 30-day mortality (population attributable fraction 26.6% (95% c.i. 14.5% to 38.6%), 18.7% (95% c.i. 9.4% to 28.0%), and 15.6% (95% c.i. 12.0% to 30.0%) respectively). Anastomotic leakage and pulmonary complications had the greatest impact on escalation of care (population attributable fraction 26.3% (95% c.i. 20.6% to 32.0%) and 18.4% (95% c.i. 11.7% to 25.2%) respectively), whereas anastomotic leakage and intra-abdominal bleeding had the greatest impact on reoperation (population attributable fraction 31.6% (95% c.i. 26.4% to 36.9%) and 8.5% (95% c.i. 5.5% to 11.5%) respectively). Most of the studied complications contributed to a prolonged hospital stay, whereas the contribution of complications to readmission did not exceed 15.9%. Subgroup analysis showed regional variation in the impact of complications. Conclusion Anastomotic leakage had the largest overall negative impact on clinical outcomes after gastrectomy for gastric adenocarcinoma. Reducing the incidence of anastomotic leakage and pulmonary complications would have the most impact on the burden of complications.

  Oxford University Press (OUP), Mar. 2025, British Journal of Surgery, 112(4) (4)

  Scientific journal


• Reconstruction Techniques and Associated Morbidity in Minimally Invasive Gastrectomy for Cancer: Insights From the GastroBenchmark and GASTRODATA databases.

  Marcel André Schneider, Jeesun Kim, Felix Berlth, Yutaka Sugita, Peter P Grimminger, Bas P L Wijnhoven, Hidde Overtoom, Ines Gockel, René Thieme, Ewen A Griffiths, William Butterworth, Henrik Nienhüser, Beat Müller, Nerma Crnovrsanin, Daniel Gero, Felix Nickel, Suzanne Gisbertz, Mark I van Berge Henegouwen, Philip H Pucher, Kashuf Khan, Asif Chaudry, Pranav H Patel, Manuel Pera, Mariagiulia Dal Cero, Carlos Garcia, Guillermo Martinez Salinas, Paulo Kassab, Osvaldo Antônio Prado Castro, Enrique Norero, Paul Wisniowski, Luke Randall Putnam, Pietro Maria Lombardi, Giovanni Ferrari, Rita Gudaityte, Almantas Maleckas, Leanne Prodehl, Antonio Castaldi, Michel Prudhomme, Hyuk-Joon Lee, Takeshi Sano, Gian Luca Baiocchi, Giovanni De Manzoni, Simone Giacopuzzi, Maria Bencivenga, Riccardo Rosati, Francesco Puccetti, Domenico D'Ugo, Souya Nunobe, Han-Kwang Yang, Christian Alexander Gutschow

  OBJECTIVE/BACKGROUND: Various anastomotic and reconstruction techniques are used for minimally invasive total (miTG) and distal gastrectomy (miDG). Their effects on postoperative morbidity have not been extensively studied. METHODS: MiTG and miDG patients were selected from 9356 oncological gastrectomies performed in 2017-2021 in 43 centers. Endpoints included anastomotic leakage (AL) rate and postoperative morbidity tested by multivariable analysis. RESULTS: Three major anastomotic techniques [circular stapled (CS); linear stapled (LS); and hand sewn (HS)], and 3 major bowel reconstruction types [Roux (RX); Billroth I (BI); Billroth II (BII)] were identified in miTG (n=878) and miDG (n=3334). Postoperative complications, including AL (5.2% vs 1.1%), overall (28.7% vs 16.3%), and major morbidity (15.7% vs 8.2%), as well as 90-day mortality (1.6% vs 0.5%) were higher after miTG compared with miDG. After miTG, the AL rate was higher after CS (4.3%) and HS (7.9%) compared with LS (3.4%). Similarly, major complications (LS: 9.7%, CS: 16.2%, and HS: 12.7%) were lowest after LS. Multivariate analysis confirmed anastomotic technique as a predictive factor for AL, overall, and major complications. In miDG, AL rate (BI: 1.4%, BII 0.8%, and RX 1.2%), overall (BI: 14.5%, BII: 15.0%, and RX: 18.7%), and major morbidity (BI: 7.9%, BII: 9.1%, and RX: 7.2%), and mortality (BI: 0%, BII: 0.1%, and RY: 1.1%%) were not affected by bowel reconstruction. CONCLUSIONS: In oncologically suitable situations, miDG should be preferred to miTG, as postoperative morbidity is significantly lower. LS should be a preferred anastomotic technique for miTG in Western Centers. Conversely, bowel reconstruction in DG may be chosen according to the surgeon's preference.

  Nov. 2024, Annals of surgery, 280(5) (5), 788 - 798, English, International magazine

  Scientific journal


• Defining benchmarks for total and distal gastrectomy: global multicentre analysis.

  Marcel André Schneider, Jeesun Kim, Felix Berlth, Yutaka Sugita, Peter P Grimminger, Takeshi Sano, Riccardo Rosati, Gian Luca Baiocchi, Maria Bencivenga, Giovanni De Manzoni, Souya Nunobe, Han-Kwang Yang, Christian Alexander Gutschow

  Jan. 2024, The British journal of surgery, 111(2) (2), English, International magazine

  Scientific journal


• CD244+ polymorphonuclear myeloid‑derived suppressor cells reflect the status of peritoneal dissemination in a colon cancer mouse model

  Yutaka Sugita, Kimihiro Yamashita, Mitsugu Fujita, Masafumi Saito, Kota Yamada, Kyosuke Agawa, Akihiro Watanabe, Eiji Fukuoka, Hiroshi Hasegawa, Shingo Kanaji, Taro Oshikiri, Takeru Matsuda, Tetsu Nakamura, Satoshi Suzuki, Yoshihiro Kakeji

  Despite the recent development of chemotherapeutic agents, the prognosis of colorectal cancer (CRC) patients with peritoneal dissemination (PD) remains poor. The tumor immune microenvironment (TIME) has drawn attention as a key contributing factor of tumor progression. Of TIME components, myeloid‑derived suppressor cells (MDSCs) are considered to play a responsible role in the immunosuppressive characteristics of the TIME. MDSCs are classified into two major subsets: Monocytic MDSCs (M‑MDSCs) and polymorphonuclear MDSCs (PMN‑MDSCs). Therefore, we hypothesize that MDSCs would play important roles in the PD‑relevant TIME and PD progression. To address this hypothesis, we established PD mouse models. As the PD nodules consisted scarcely of immune cells, we focused on the peritoneal cavity, but not PD nodule, to evaluate the PD‑relevant TIME. As a result, intraperitoneal PMN‑MDSCs were found to be substantially increased in association with PD progression. Based on these results, we phenotypically and functionally verified the usefulness of CD244 for identifying PMN‑MDSCs. In addition, the concentrations of interleukin (IL)‑6 and granulocyte‑colony stimulating factor (G‑CSF) were significantly increased in the peritoneal cavity, both of which were produced by the tumors and thought to contribute to the increases in the PMN‑MDSCs. In vivo depletion of the PMN‑MDSCs by anti‑Ly6G monoclonal antibody (mAb) significantly inhibited the PD progression and reverted CD4+ and CD8+ T cells in the peritoneal cavity and the peripheral blood. Collectively, these results suggest that the targeted therapy for PMN‑MDSCs would provide not only new therapeutic value but also a novel strategy to synergize with T‑cell‑based immunotherapy for CRC‑derived PD.

  Lead, Spandidos Publications, Apr. 2021, Oncology Reports, 45(6) (6), English, International magazine

  Scientific journal


• Safety and feasibility of minimally invasive esophagectomy for elderly esophageal cancer patients

  Y Sugita, T Nakamura, R Sawada, G Takiguchi, N Urakawa, H Hasegawa, M Yamamoto, S Kanaji, Y Matsuda, K Yamashita, T Matsuda, T Oshikiri, S Suzuki, Y Kakeji

  The number of elderly patients with esophageal cancer has increased in recent years. The use of thoracoscopic esophagectomy has also increased, and its minimal invasiveness is believed to contribute to postoperative outcomes. However, the short- and long-term outcomes in elderly patients remain unclear. This study aimed to elucidate the safety and feasibility of minimally invasive esophagectomy in elderly patients. This retrospective study included 207 patients who underwent radical thoracoscopic esophagectomy for thoracic esophageal squamous cell carcinoma at Kobe University Hospital between 2005 and 2014. Patients were divided into non-elderly (&lt;75 years) and elderly (≥75 years) groups. A propensity score matching analysis was performed for sex and clinical T and N stage, with a total of 29 matched pairs. General preoperative data, surgical procedures, intraoperative data, postoperative complications, in-hospital death, cancer-specific survival, and overall survival were compared between groups. The elderly group was characterized by lower preoperative serum albumin levels and higher American Society of Anesthesiologists grade. Intraoperative data and postoperative complications did not differ between the groups. The in-hospital death rate was 4% in the elderly group, which did not significantly differ from the non-elderly group. Cancer-specific survival was similar between the two groups. Although overall survival tended to be poor in the elderly group, it was not significantly worse than that of the non-elderly group. In conclusion, the short- and long-term outcomes of minimally invasive esophagectomy in elderly versus non-elderly patients were acceptable. Minimally invasive esophagectomy is a safe and feasible modality for elderly patients with appropriate indications.

  Lead, Oxford University Press (OUP), Sep. 2020, Diseases of the Esophagus, 34(3) (3), English, International magazine

  [Refereed]

  Scientific journal


• Neoadjuvant Chemotherapy Increases PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Esophageal Squamous Cell Carcinoma.

  Eiji Fukuoka, Kimihiro Yamashita, Tomoko Tanaka, Ryuichiro Sawada, Yutaka Sugita, Akira Arimoto, Mitsugu Fujita, Gosuke Takiguchi, Takeru Matsuda, Taro Oshikiri, Tetsu Nakamura, Satoshi Suzuki, Yoshihiro Kakeji

  BACKGROUND/AIM: The aim of this study was to investigate PD-L1 expression and its association with prognosis in esophageal squamous cell carcinoma (ESCC) before and after neoadjuvant chemotherapy (5-fluorouracil and cisplatin, NAC-FP). PATIENTS AND METHODS: Using a database of 69 ESCC patients, we analyzed PD-L1 expression on tumor cells (TCs) and immune cells (ICs), as well as the density of CD8+ tumor-infiltrating lymphocytes (TILs) in pretreatment biopsy specimens-versus-surgical specimens after resection. We determined the prognostic significance of these factors. RESULTS: The fraction of ESCC containing ICs expressing PD-L1 and having a high CD8+ TIL density was significantly increased after neoadjuvant treatment. However, PD-L1 expression on TCs or ICs, and CD8+ TIL density, was not significantly associated with patient survival in ESCC patients. CONCLUSION: NAC-FP induced PD-L1 expression on ICs and CD8+ TILs in ESCC patients. This finding suggests that PD-1/PD-L1 blockade could be combined with NAC-FP to treat ESCC patients.

  Aug. 2019, Anticancer research, 39(8) (8), 4539 - 4548, English, International magazine

  [Refereed]

  Scientific journal


• 高齢者胃癌の外科治療

  鈴木 知志, 金治 新悟, 山本 将士, 松田 佳子, 杉田 裕, 掛地 吉弘

  Apr. 2019, 癌の臨床, 64(4) (4), 257 - 264, Japanese

  [Refereed]

  Scientific journal


• Application of iNKT Cell-targeted Active Immunotherapy in Cancer Treatment.

  Kimihiro Yamashita, Akira Arimoto, Masayasu Nishi, Tomoko Tanaka, Mitsugu Fujita, Eiji Fukuoka, Yutaka Sugita, Akio Nakagawa, Hiroshi Hasegawa, Satoshi Suzuki, Yoshihiro Kakeji

  In tumor immunity, invariant natural killer T (iNKT) cells play a pivotal role as a link between the innate and adaptive immune systems. With a precisely regulated activation mechanism, iNKT cells have the ability to respond quickly to antigenic stimulation and rapidly produce cytokines and chemokines, and subsequently an effective antitumor immune response. The development of iNKT cell-targeted active immunotherapy enables, not only an antitumor immune response through innate and acquired immunity, but also the conversion of an immunosuppressive into an immunogenic microenvironment. This review is focused on the activation mechanism and the role of iNKT cells after therapeutic active immunization. The therapeutic strategy targeting iNKT cells is expected to be applied to clinical practice in combination with surgery and chemotherapy.

  Jul. 2018, Anticancer research, 38(7) (7), 4233 - 4239, English, International magazine

  [Refereed]

  Scientific journal


• Immunosuppression Induced by Perioperative Peritonitis Promotes Lung Metastasis.

  Arimoto A, Yamashita K, Hasegawa H, Sugita Y, Fukuoka E, Tanaka T, Suzuki S, Kakeji Y

  Jul. 2018, Anticancer research, 38(7) (7), 4333 - 4338

  [Refereed]


• 大腸ESD後穿孔症例に対するクリッピング閉鎖の有効性について

  杉田 裕, 長谷川 寛, 松田 武, 山下 公大, 角 泰雄, 前原 律子, 東野 展英, 山本 将士, 金治 新悟, 松田 佳子, 押切 太郎, 中村 哲, 鈴木 知志, 掛地 吉弘

  (一社)日本消化器外科学会, Oct. 2017, 日本消化器外科学会雑誌, 50(Suppl.2) (Suppl.2), 383 - 383, Japanese


• Frequency of Myeloid-derived Suppressor Cells in the Peripheral Blood Reflects the Status of Tumor Recurrence

  Tomoko Tanaka, Mitsugu Fujita, Hiroshi Hasegawa, Akira Arimot, Masayasu Nishi, Eiji Fukuoka, Yutaka Sugita, Takeru Matsuda, Yasuo Sumi, Satoshi Suzuki, Yoshihiro Kakeji, Kimihiro Yamashita

  Jul. 2017, ANTICANCER RESEARCH, 37(7) (7), 3863 - 3869, English

  [Refereed]

  Scientific journal


• Simple and reliable method for tumor localization during totally laparoscopic gastrectomy: intraoperative laparoscopic ultrasonography combined with tattooing

  Takeru Matsuda, Takeshi Iwasaki, Kenro Hirata, Daisuke Tsugawa, Yutaka Sugita, Sonoko Ishida, Shingo Kanaji, Yoshihiro Kakeji

  May 2017, GASTRIC CANCER, 20(3) (3), 548 - 552, English

  [Refereed]

  Scientific journal


• A Simple and Reliable Method for Intracorporeal Circular-Stapled Esophagojejunostomy Using a Hand-Sewn Over-and-Over Suture Technique in Laparoscopic Total Gastrectomy

  Takeru Matsuda, Takeshi Iwasaki, Masaaki Mitsutsuji, Kenro Hirata, Daisuke Tsugawa, Yutaka Sugita, Etsuji Shimada, Yoshihiro Kakeji

  Dec. 2015, ANNALS OF SURGICAL ONCOLOGY, 22, S355 - S355, English

  [Refereed]

  Scientific journal


• A Three-Step Method for Laparoscopic Mobilization of the Splenic Flexure

  Takeru Matsuda, Takeshi Iwasaki, Kenro Hirata, Daisuke Tsugawa, Yutaka Sugita, Yasuo Sumi, Yoshihiro Kakeji

  Dec. 2015, ANNALS OF SURGICAL ONCOLOGY, 22, S335 - S335, English

  [Refereed]

  Scientific journal


• Surgical outcomes of intracorporeal circular-stapled esophagojejunostomy using modified over-and-over suture technique in laparoscopic total gastrectomy

  Takeru Matsuda, Takeshi Iwasaki, Masaaki Mitsutsuji, Kenro Hirata, Yoko Maekawa, Daisuke Tsugawa, Yutaka Sugita, Etsuji Shimada, Yoshihiro Kakeji

  Nov. 2015, SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 29(11) (11), 3386 - 3391, English

  [Refereed]

  Scientific journal


• Cranially approached radical lymph node dissection around the middle colic vessels in laparoscopic colon cancer surgery

  T. Matsuda, T. Iwasaki, M. Mitsutsuji, K. Hirata, Y. Maekawa, D. Tsugawa, Y. Sugita, Y. Sumi, E. Shimada, Y. Kakeji

  Urban und Vogel GmbH, Jun. 2015, Coloproctology, 37(3) (3), 165 - 169, German

  [Refereed]

  Scientific journal


• Cranially approached radical lymph node dissection around the middle colic vessels in laparoscopic colon cancer surgery

  Takeru Matsuda, Takeshi Iwasaki, Masaaki Mitsutsuji, Kenro Hirata, Yoko Maekawa, Daisuke Tsugawa, Yutaka Sugita, Yasuo Sumi, Etsuji Shimada, Yoshihiro Kakeji

  Jan. 2015, LANGENBECKS ARCHIVES OF SURGERY, 400(1) (1), 113 - 117, English

  [Refereed]

  Scientific journal

• PMN-MDSCs Cause Disease Progression Peritoneal Dissemination of Colorectal Cancer.

  山下公大, 杉田裕, 斎藤雅史, 山田康太, 阿河杏介, 長谷川寛, 金治新悟, 松田武, 押切太郎, 掛地吉弘

  2022, 日本がん転移学会学術集会・総会プログラム抄録集, 31st


• 高齢者における食道癌手術の現状と課題 高齢患者に対する胸腔鏡下食道切除術の安全性と有効性(Safety and validity of thoracoscopic esophagectomy for elderly patients)

  渡部 晃大, 押切 太郎, 杉田 裕, 裏川 直樹, 長谷川 寛, 金治 新悟, 山下 公大, 松田 武, 中村 哲, 鈴木 知志, 掛地 吉弘

  (NPO)日本食道学会, Sep. 2021, 日本食道学会学術集会プログラム・抄録集, 75回, 57 - 57, English


• The induction of PD-L1 positive immune cells and CD8-positive T lymphocytes by neoadjuvant chemoradiotherapy for rectal cancer

  Kimihiro Yamashita, Akio Nakagawa, Tomoko Tanaka, Akira Arimoto, Eiji Fukuoka, Yutaka Sugita, Junko Mukohyama, Piero Dalerba, Hiroshi Hasegawa, Takeru Matsuda, Satoshi Suzuki, Yoshihiro Kakeji

  Jul. 2018, CANCER RESEARCH, 78(13) (13), English

  Summary international conference

• 腹膜播種における腹腔内腫瘍免疫微小環境の解析

  杉田裕, 山下公大, 福岡英志, 渡部晃大, 瀧口豪介, 浦川直樹, 長谷川寛, 山本将士, 金治新悟, 松田佳子, 松田武, 押切太郎, 中村哲, 鈴木知志, 掛地吉弘

  第30回日本消化器癌発生学会総会, Nov. 2019


• 局所進行胃癌に対するneoadjuvant cheterapyとしてのSOX療法の安全性

  松田佳子, 杉田 裕, 瀧口 豪介, 裏川 直樹, 長谷川 寛, 山本 将士, 金治 新悟, 山下 公大, 松田 武, 押切 太郎, 中村 哲, 鈴木 知志, 掛地 吉弘

  第57回日本癌治療学会学術集会, Oct. 2019, Japanese, 岐阜大学大学院医学系研究科 脳腫瘍制御学講座 腫瘍外科学分野, 福岡, Domestic conference

  Poster presentation


• 当科で術前化学療法を施行した腎機能障害を有する胃癌症例の検討

  松田 佳子, 杉田 裕, 山本 将士, 金治 新悟, 山下 公大, 押切 太郎, 松田 武, 中村 哲, 鈴木 知志, 掛地 吉弘

  第74回日本消化器外科学会総会, Jul. 2019, Japanese, 東京慈恵会医科大学, 東京, Domestic conference

  Poster presentation


• 高齢者の胃癌切除におけるCONUT scoreによるフレイル判定の有用性

  杉田 裕, 鈴木 知志, 裏川 直樹, 金治 新悟, 山本 将士, 松田 佳子, 瀧口 豪介, 長谷川 寛, 山下 公大, 松田 武, 押切 太郎, 中村 哲, 掛地 吉弘

  第44回日本外科系連合学会学術集会, Jun. 2019, Japanese, 金沢医科大学 一般・消化器外科学, 金沢, Domestic conference

  Public symposium


• 高齢食道癌患者に対する胸腔鏡手術の妥当性

  杉田 裕, 押切 太郎, 澤田 隆一郎, 三浦 晋, 山下 公大, 松田 武, 中村 哲, 鈴木 知志, 掛地 吉弘

  第73回日本食道学会学術集会, Jun. 2019, Japanese, 独立行政法人国立病院機構 九州がんセンター, 福岡, Domestic conference

  Poster presentation


• αガラクトシルセラミド付加した抗原導入した樹状細胞ベクターの抗腫瘍効果

  渡部 晃大, 山下 公大, 有本 聡, 西 将康, 杉田 裕, 福岡 英志, 長谷川 寛, 山本 将士, 金治 新悟, 松田 佳子, 松田 武, 押切 太郎, 中村 哲, 鈴木 知志, 掛地 吉弘

  第29回日本サイトメトリー学会学術集会, May 2019, Japanese, 順天堂大学医学部内科学血液学講座, 東京, Domestic conference

  Oral presentation


• 腹膜播種マウスモデルにおける腹腔内骨髄由来抑制細胞（MDSC）の検討

  杉田 裕, 山下 公大, 渡部 晃大, 福岡 英志, 有本 聡, 長谷川 寛, 山本 将士, 金治 新悟, 松田 佳子, 松田 武, 押切 太郎, 中村 哲, 鈴木 知志, 掛地 吉弘

  第29回日本サイトメトリー学会学術集会, May 2019, Japanese, 順天堂大学医学部内科学血液学講座, 東京, Domestic conference

  Oral presentation


• 消化器癌患者の末梢血T細胞におけるimmunological synapseの評価

  杉田 裕, 山下 公大, 田中 智子, 渡部 晃大, 福岡 英志, 有本 聡, 瀧口 豪介, 高瀬 信尚, 長谷川 寛, 山本 将士, 金治 新悟, 松田 佳子, 松田 武, 押切 太郎, 中村 哲, 鈴木 知志, 掛地 吉弘

  第40回癌免疫外科研究会, May 2019, Japanese, 金沢大学 消化器・腫瘍・再生外科学, 金沢, Domestic conference

  Public symposium


• タンパク抗原を導入したNKT細胞活性化樹状細胞ワクチンベクターの抗腫瘍効果

  山下 公大, 有本 聡, 西 将康, 福岡 英志, 杉田 裕, 渡部 晃大, 長谷川 寛, 瀧口 豪介, 山本 将士, 金治 新悟, 松田 佳子, 押切 太郎, 松田 武, 中村 哲, 鈴木 知志, 掛地 吉弘

  第40回癌免疫外科研究会, May 2019, Japanese, 金沢大学 消化器・腫瘍・再生外科学, 金沢, Domestic conference

  Public symposium


• 局所進行胃癌に対する術前化学療法におけるSOX 療法の安全性と有効性

  松田 佳子, 杉田 裕, 高瀬 信尚, 瀧口 豪介, 長谷川 寛, 山本 将士, 金治 新悟, 山下 公大, 押切 太郎, 松田 武, 中村 哲, 鈴木 知志, 掛地 吉弘

  第119回日本外科学会定期学術集会, Apr. 2019, Japanese, 一般社団法人日本外科学会, 大阪, Domestic conference


• The induction of CD8+ T lymphocytes and PD-L1+ immune cells by neoadjuvant chemoradiotherapy for rectal cancer

  Fukuoka E, Yamashita K, Sugita Y, Arimoto A, Nakamura T, Kakeji Y

  AACR Annual Meeting 2019, Mar. 2019, Japanese, Atlanta, Domestic conference

  Poster presentation


• Intraperitoneal myeloid-derived suppressor cells in peritoneal dissemination mouse model

  Sugita Y, Yamashita K, Takimoto R, Tanaka T, Arimoto A, Fukuoka E, Nakamura T, Suzuki S, Kakeji Y

  AACR Annual Meeting 2019, Mar. 2019, Japanese, Atlanta, Domestic conference

  Poster presentation


• 腹膜播種マウスモデルにおける腹腔内骨髄由来抑制細胞（MDSC）の検討

  杉田 裕, 山下 公大, 田中 智子, 渡部 晃大, 福岡 英志, 有本 聡, 長谷川 寛, 松田 武, 押切 太郎, 中村 哲, 鈴木 知志, 掛地 吉弘

  第52回制癌剤適応研究会, Mar. 2019, Japanese, 神戸大学大学院医学研究科外科学講座食道胃腸外科学分野, 有馬, Domestic conference

  Oral presentation


• 末梢血myeloid derived suppressor cells（MDSC）は腫瘍の再発を反映する

  田中 智子, 山下 公大, 杉田 裕, 福岡 英志, 有本 聡, 掛地 吉弘

  第52回制癌剤適応研究会, Mar. 2019, Japanese, 神戸大学大学院医学研究科外科学講座食道胃腸外科学分野, 有馬, Domestic conference

  Public symposium


• 術前化学療法を行った進行胃癌症例での再発令の検討

  松田 佳子, 杉田 裕, 長谷川 寛, 山本 将士, 金治 新悟, 山下 公大, 押切 太郎, 松田 武, 中村 哲, 鈴木 知志, 掛地 吉弘

  第91回日本胃癌学会総会, Feb. 2019, Japanese, 静岡県立静岡がんセンター 胃外科, 沼津, Domestic conference

  Poster presentation


• マウス腹膜播種モデルにおける腹腔内骨髄由来免疫抑制細胞（MDSC)の推移

  杉田 裕, 山下 公大, 福岡 英志, 田中 智子, 有本 聡, 瀧口 豪介, 高瀬 信尚, 長谷川 寛, 山本 将士, 金治 新悟, 松田 佳子, 松田 武, 押切 太郎, 中村 哲, 鈴木 知志, 掛地 吉弘

  第22回バイオ治療法研究会, Dec. 2018, Japanese, 特定非営利活動法人環瀬戸内自然免疫ネットワーク, 東京, Domestic conference

  Oral presentation


• 末梢Ｔ細胞のIS形成能の測定法の確立

  山下 公大, 田中 智子, 杉田 裕, 渡部 晃大, 福岡 英志, 有本 聡, 瀧口 豪介, 高瀬 信尚, 長谷川 寛, 山本 将士, 金治 新悟, 松田 佳子, 松田 武, 押切 太郎, 中村 哲, 鈴木 知志, 掛地 吉弘

  第22回バイオ治療法研究会, Dec. 2018, Japanese, 特定非営利活動法人環瀬戸内自然免疫ネットワーク, 東京, Domestic conference

  Oral presentation


• 食道癌患者におけるT細胞表面分子集簇による機能評価

  山下 公大, 田中 智子, 杉田 裕, 福岡 英志, 有本 聡, 松田 武, 押切 太郎, 中村 哲, 鈴木 知志, 掛地 吉弘

  第29回日本消化器癌発生学会総会, Nov. 2018, Japanese, 一般社団法人日本消化器癌発生学会, 東京, Domestic conference

  Poster presentation


• 腹膜播種モデルにおける腹腔内骨骨髄由来抑制細胞(MDSC)の推移

  杉田 裕, 山下 公大, 福岡 英志, 田中 智子, 有本 聡, 長谷川 寛, 山本 将士, 金治 新悟, 松田 佳子, 松田 武, 押切 太郎, 中村 哲, 鈴木 知志, 掛地 吉弘

  第29回日本消化器癌発生学会総会, Nov. 2018, Japanese, 一般社団法人日本消化器癌発生学会, 東京, Domestic conference

  Oral presentation


• 化学療法後に胃切除術を行った進行胃癌症例における予後因子の検討

  杉田 裕, 鈴木 知志, 長谷川 寛, 山本 将士, 金治 新悟, 松田 佳子, 山下 公大, 松田 武, 押切 太郎, 中村 哲, 掛地 吉弘

  第56回日本癌治療学会学術集会, Oct. 2018, Japanese, 一般社団法人 日本癌治療学会, 横浜, Domestic conference

  Poster presentation


• 腫瘍抗原導入DCGによる抗原特異的抗腫瘍免疫活性化

  有本 聡, 山下 公大, 西 将康, 杉田 裕, 福岡 英志, 田中 智子, 掛地 吉弘

  第77回日本癌学会学術総会, Sep. 2018, Japanese, 日本癌学会, 大阪, Domestic conference

  Poster presentation


• 直腸癌術前化学放射線療法によるCD８+T細胞とPD-L1陽性免疫細胞の誘導

  福岡 英志, 山下 公大, 中川 暁雄, 田中 智子, 有本 聡, 杉田 裕, 長谷川 寛, 松田 武, 中村 哲, 鈴木 知志, 掛地 吉弘

  第77回日本癌学会学術総会, Sep. 2018, Japanese, 日本癌学会, 大阪, Domestic conference

  Oral presentation


• T細胞刺激後免疫シナプス様表面分子の集簇反応の評価

  山下 公大, 田中 智子, 岡 祐馬, 森田 愛梨, 柳田 匡俊, 杉田 裕, 福岡 英志, 有本 聡, 松田 武, 中村 哲, 鈴木 知志, 掛地 吉弘

  第77回日本癌学会学術総会, Sep. 2018, Japanese, 日本癌学会, 大阪, Domestic conference

  Poster presentation


• 消化器癌患者におけるT細胞の刺激応答性の評価方法の検討

  田中 智子, 山下 公大, 岡 祐馬, 柳田 匡俊, 杉田 裕, 福岡 英志, 有本 聡, 長谷川 寛, 山本 将士, 金治 新悟, 松田 佳子, 押切 太郎, 松田 武, 中村 哲, 鈴木 知志, 掛地 吉弘

  第22回日本がん免疫学会総会, Aug. 2018, Japanese, 日本がん免疫学会, 岡山, Domestic conference

  Poster presentation


• 術後腹膜炎が肺転移の予後に及ぼす影響とその免疫学的検討

  有本 聡, 山下 公大, 長谷川 寛, 杉田 裕, 福岡 英志, 田中 智子, 金治 新悟, 松田 佳子, 松田 武, 押切 太郎, 中村 哲, 角 泰雄, 鈴木 知志, 掛地 吉弘

  第27回日本がん転移学会学術集会・総会, Jul. 2018, Japanese, 日本がん転移学会, 横浜, Domestic conference

  Public symposium


• 切除可能進行胃癌における術前補助化学療法の予後因子の検討

  杉田 裕, 鈴木 知志, 山本 将士, 金治 新悟, 松田 佳子, 松田 武, 押切 太郎, 中村 哲, 角 泰雄, 掛地 吉弘

  第73回日本消化器外科学会総会, Jul. 2018, Japanese, 一般社団法人 日本消化器外科学会, 鹿児島, Domestic conference

  Poster presentation


• 後期高齢者進行胃癌患者に対する術前化学療法の安全性

  松田 佳子, 杉田 裕, 山本 将士, 金治 新悟, 松田 武, 押切 太郎, 角 泰雄, 中村 哲, 鈴木 知志, 掛地 吉弘

  第73回日本消化器外科学会総会, Jul. 2018, Japanese, 一般社団法人 日本消化器外科学会, 鹿児島, Domestic conference

  Poster presentation


• 消化器癌患者におけるT細胞表面分子集簇による機能評価

  山下 公大, 田中 智子, 杉田 裕, 福岡 英志, 有本 聡, 山本 将士, 押切 太郎, 中村 哲, 鈴木 知志, 掛地 吉弘

  第73回日本消化器外科学会総会, Jul. 2018, Japanese, 一般社団法人 日本消化器外科学会, 鹿児島, Domestic conference

  Poster presentation


• 高齢者における術前化学療法の安全性と栄養評価

  杉田 裕, 松田 佳子, 長谷川 寛, 山本 将士, 金治 新悟, 山下 公大, 押切 太郎, 松田 武, 中村 哲, 角 泰雄, 鈴木 知志, 掛地 吉弘

  日本外科代謝栄養学会第55回学術集会, Jul. 2018, Japanese, 日本外科代謝栄養学会, 大阪, Domestic conference

  Oral presentation


• 高齢者の胃癌治癒切除後の予後予測におけるCONUT scoreの有用性

  鈴木 知志, 金治 新悟, 山本 将士, 松田 佳子, 杉田 裕, 長谷川 寛, 山下 公大, 松田 武, 押切 太郎, 中村 哲, 掛地 吉弘

  日本外科代謝栄養学会第55回学術集会, Jul. 2018, Japanese, 日本外科代謝栄養学会, 大阪, Domestic conference

  Oral presentation


• 高齢者胃癌患者における術後肺炎併発の長期予後への影響

  杉田 裕, 鈴木 知志, 長谷川 寛, 山本 将士, 金治 新悟, 松田 佳子, 山下 公大, 松田 武, 押切 太郎, 角 泰雄, 中村 哲, 掛地 吉弘

  第43回日本外科系連合学会学術集会, Jun. 2018, Japanese, 一般社団法人 学会支援機構内日本外科系連合学会事務局, 東京, Domestic conference

  Public symposium


• 癌患者におけるT細胞の刺激応答性の評価???

  山下 公大, 田中 智子, 杉田 裕, 福岡 英志, 有本 聡, 長谷川 寛, 山本 将士, 金治 新悟, 松田 佳子, 押切 太郎, 松田 武, 中村 哲, 角 泰雄, 鈴木 知志, 掛地 吉弘

  第27回日本癌病態治療研究会, May 2018, Japanese, NPO法人 日本癌病態治療研究会事務局, 千葉, Domestic conference

  Public symposium


• 消化器癌患者におけるT細胞の刺激応答性の新規評価方法

  田中 智子, 山下 公大, 岡 祐馬, 森田 愛梨, 柳田 匡俊, 杉田 裕, 福岡 英志, 有本 聡, 長谷川 寛, 松田 武, 中村 哲, 鈴木 知志, 掛地 吉弘

  第28回日本サイトメトリー学会学術集会, May 2018, Japanese, 一般社団法人日本サイトメトリー学会, 東京, Domestic conference

  Poster presentation


• 腫瘍再発モデルにおける末梢血中の骨髄由来抑制細胞(MDSC)の推移

  杉田 裕, 山下 公大, 田中 智子, 福岡 英志, 有本 聡, 長谷川 寛, 山本 将士, 金治 新悟, 松田 佳子, 松田 武, 押切 太郎, 角 泰雄, 中村 哲, 鈴木 知志, 掛地 吉弘

  第6回がんと代謝研究会, May 2018, Japanese, がんと代謝研究会, 奄美大島, Domestic conference

  Poster presentation


• Electroporation as a feasible method for antigen delivering into vectors loaded with NKT cell ligand

  Arimoto A, Nishi M, Yamashita K, Sugita Y, Fukuoka E, Tanaka T, Kamigaki T, Takimoto R, Kakeji Y

  AACR Annual Meeting 2018, Apr. 2018, English, American Association for Cancer Research, Chicago, International conference

  Poster presentation


• The induction of PD-L1 positive immune cells and CD8-positive T lymphocytes by neoadjuvant chemoradiotherapy for rectal cancer

  Yamashita K, Nakagawa A, Tanaka T, Arimoto A, Fukuoka E, Sugita Y, Mukoyama J, Dalerba P, Hasegawa H, Matsuda T, Suzuki S, Kakeji Y

  AACR Annual Meeting 2018, Apr. 2018, English, American Association for Cancer Research, Chicago, International conference

  Poster presentation


• A new method for evaluating T cell response after stimulation on gastrointestinal cancer patients

  Tanaka T, Yamashita K, Sugita Y, Fukuoka E, Arimoto A, Kakeji Y

  AACR Annual Meeting 2018, Apr. 2018, English, American Association for Cancer Research, Chicago, International conference

  Poster presentation


• 化学療法後に胃切除術を行った進行胃癌症例の検討

  松田 佳子, 杉田 裕, 長谷川 寛, 山本 将士, 金治 新悟, 山下 公大, 松田 武, 押切 太郎, 角 泰雄, 中村 哲, 鈴木 知志, 掛地 吉弘

  第51回制癌剤適応研究会, Mar. 2018, Japanese, 制癌剤適応研究会, 下呂, Domestic conference

  Oral presentation


• 神経内分泌細胞成分を伴う胃癌に対する集学的治療の有用性

  杉田 裕, 鈴木 知志, 金治 新悟, 松田 佳子, 山本 将士, 長谷川 寛, 山下 公大, 押切 太郎, 松田 武, 中村 哲, 角 泰雄, 掛地 吉弘

  第90回日本胃癌学会総会, Mar. 2018, Japanese, 日本胃癌学会, 横浜, Domestic conference

  Poster presentation


• 神経内分泌細胞成分を含む胃癌に対する集学的治療の有用性

  杉田 裕, 鈴木 知志, 金治 新悟, 松田 佳子, 山本 将士, 長谷川 寛, 山下 公大, 押切 太郎, 松田 武, 角 泰雄, 中村 哲, 掛地 吉弘

  第14回日本消化管学会総会学術集会, Feb. 2018, Japanese, 一般社団法人日本消化管学会, 東京, Domestic conference

  Public symposium


• 腫瘍抗原導入DCGを用いた抗原特異的抗腫瘍免疫活性化

  西 将康, 山下 公大, 長谷川 寛, 田中 智子, 有本 聡, 杉田 裕, 福岡 英志, 山本 将士, 金治 新悟, 松田 佳子, 松田 武, 押切 太郎, 角 泰雄, 中村 哲, 鈴木 知志, 掛地 吉弘

  第21回バイオ治療法研究会学術集会, Dec. 2017, Japanese, 福岡がん総合クリニック, 福岡, Domestic conference

  Oral presentation


• 術後腹膜炎が肺転移の予後に及ぼす影響とその免疫学的検討

  有本 聡, 長谷川 寛, 山下 公大, 杉田 裕, 福岡 英志, 田中 智子, 西 将康, 山本 将士, 金治 新悟, 松田 佳子, 松田 武, 押切 太郎, 角 泰雄, 中村 哲, 鈴木 知志, 掛地 吉弘

  第21回バイオ治療法研究会学術集会, Dec. 2017, Japanese, 福岡がん総合クリニック, 福岡, Domestic conference

  Oral presentation


• 術後腹膜炎が肺転移の予後に及ぼす影響とその免疫学的検討

  有本 聡, 長谷川 寛, 山下 公大, 杉田 裕, 福岡 英志, 田中 智子, 西 将康, 山本 将士, 金治 新悟, 松田 佳子, 松田 武, 押切 太郎, 中村 哲, 角 泰雄, 鈴木 知志, 掛地 吉弘

  第28回日本消化器癌発生学会, Nov. 2017, Japanese, 熊本大学大学院生命科学研究部 消化器外科学, 熊本, Domestic conference

  Oral presentation


• 腫瘍再発モデルにおける末梢血中の骨髄由来抑制細胞（MDSC）の推移

  杉田 裕, 田中 智子, 山下 公大, 福岡 英志, 有本 聡, 西 将康, 長谷川 寛, 山本 将士, 金治 新悟, 松田 佳子, 松田 武, 押切 太郎, 角 泰雄, 中村 哲, 鈴木 知志, 掛地 吉弘

  第28回日本消化器癌発生学会, Nov. 2017, Japanese, 熊本大学大学院生命科学研究部 消化器外科学, 熊本, Domestic conference

  Oral presentation


• 消化器癌患者におけるT細胞の刺激応答性の評価方法の検討

  田中 智子, 山下 公大, 岡 祐馬, 森田 愛梨, 柳田 匡俊, 杉田 裕, 福岡 英志, 有本 聡, 西 将康, 長谷川 寛, 松田 武, 角 泰雄, 鈴木 知志, 掛地 吉弘

  第28回日本消化器癌発生学会, Nov. 2017, Japanese, 熊本大学大学院生命科学研究部 消化器外科学, 熊本, Domestic conference

  Oral presentation


• 大腸ESD後穿孔症例に対するクリッピング閉鎖の有効性について

  杉田 裕, 長谷川 寛, 松田 武, 山下 公大, 角 泰雄, 前原 律子, 東野 展英, 山本 将士, 金治 新悟, 松田 佳子, 押切 太郎, 中村 哲, 鈴木 知志, 掛地 吉弘

  JDDW2017, Oct. 2017, Japanese, 福岡, Domestic conference

  Poster presentation


• Early gastric cancer accompanied by Menetrier's disease with difficulty in pueoperative diagnosis（術前進行度診断が困難であったMenetrier病合併早期胃癌の一例）

  杉田 裕, 鈴木 知志, 山本 将士, 金治 新悟, 松田 佳子, 押切 太郎, 中村 哲, 大澤 正人, 中本 光春, 掛地 吉弘

  第89回日本胃癌学会総会, Mar. 2017, Japanese, 広島大学大学院医歯薬保健学研究科分子病理学, Domestic conference

  Poster presentation


• 検診で偶然発見された副腎外傍神経節腫の一例

  杉田 裕, 大澤 正人, 田中 智子, 小野 真義, 竹長 真紀, 中本 光春

  第181回兵庫県外科医会学術集会, Oct. 2016


• 腹腔鏡下胃切除における胃切離ラインの決定：新たな知見に基づく術中超音波（ILUS）の有用性

  松田 武, 平田 健郎, 津川 大介, 杉田 裕, 石田 苑子, 岩崎 武

  第71回日本消化器外科学会総会, Jul. 2016, Japanese, 徳島大学 消化器・移植外科学, 徳島, Domestic conference

  Poster presentation


• Laparoscopic right hemicolectomy using a cranial approach: Technical tips

  Matsuda T, Iwasaki T, Hirata K, Tsugawa D, Sugita Y, Ishida S, Sumi Y, Kakeji Y

  24th International congress of the European Association for Endoscopic Surgery, Jun. 2016, English, Amsterdam, International conference

  Oral presentation


• Trastuzumab単剤療法により長期ＣＲ維持を得た胃癌肝転移の一例

  杉田 裕, 松田 武, 平田 建郎, 岩﨑 武

  第77回日本臨床外科学会総会, Nov. 2015


• 胆石イレウスに対して腹腔鏡補助下イレウス解除術を施行した一例

  杉田 裕, 津川 大介, 平田 建郎, 松田 武, 光辻 理顕, 岩﨑 武, 島田 悦司

  第30回須磨区医師会学術集談会, Mar. 2015


• ESDを契機に発症したと考えられる急性虫垂炎の一例

  杉田 裕, 角 泰雄, 山下 公大, 金光 聖哲, 金治 新悟, 山本 将士, 今西 達也, 中村 哲, 鈴木 知志, 田中 賢一, 掛地 吉弘

  第195回近畿外科学会, May 2014, Japanese, 近畿外科学会, 天王寺, Domestic conference

  Oral presentation


• 膵頭十二指腸切除術後難治性膵液瘻に対し膵空腸再吻合を施行した一例

  杉田 裕, 後藤直大, 松本逸平, 新関 亮, 浅利貞毅, 石田 潤, 山下博成, 田中正樹, 蔵満 薫, 田中基文, 武部敦志, 岡崎太郎, 木戸正浩, 味木徹夫, 福本 巧, 具 英成

  日本消化器病学会近畿支部第100回例会, Feb. 2014


• 主膵管との交通を認め術前診断が 困難であった膵粘液性嚢胞腫瘍(MCN)の1切除例

  杉田 裕, 後藤直大, 松本逸平, 新関 亮, 浅利貞毅, 石田 潤, 山下博成, 田中正樹, 蔵満 薫, 武部敦志, 岡崎太郎, 木戸正浩, 味木徹夫, 福本 巧, 具 英成

  第75回日本臨床外科学会総会, Nov. 2013


• 68Ga-DOTATOC-PETにて十二指腸原発巣を指摘し得た転移性肝神経内分泌腫瘍の一例

  杉田 裕, 田中基文, 木戸正浩, 武部敦志, 蔵満 薫, 木下秘我, 小松昇平, 福島健司, 浦出剛史, 宗 慎一, 新関 亮, 松本逸平, 味木徹夫, 福本 巧, 具 英成

  第194回近畿外科学会, Nov. 2013

• Novel peritoneal seeding therapy using NKT cell activation vector focused on anti-PD-1 antibody resistance mechanism

  Sugita Yutaka

  Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Early-Career Scientists, Kobe University, 01 Apr. 2020 - 31 Mar. 2022

  The tumor microenvironment is composed not only of tumor cells, but also of various immune cells and stromal cells. Among them, Myeloid-derived suppressor cells (MDSCs) are suppressor immune cells and are involved in the establishment of the tumor microenvironment. On the other hand, there have been few reports on peritoneal seeding, and the studies are still insufficient. In this study, we created a mouse model of peritoneal dissemination of colorectal cancer, analyzed the dynamics of intraperitoneal MDSCs, and examined their involvement in the pathogenesis of peritoneal dissemination. The results showed that intraperitoneal MDSCs increased with disease progression after intraperitoneal administration of MC38. The proportion of PMN-MDSCs increased especially in the peritoneal cavity. Anti-Ly6G antibody-induced MDSC disappearance studies inhibited tumor progression.
  Translated with www.DeepL.com/Translator (free version)


• A new method for evaluating T cell response after stimulation on advanced esophageal cancer patients

  TANAKA TOMOKO, OKA Yuma, YANAGIDA Masatoshi, SUGITA Yutaka, FUKUOKA Eiji, ARIMOTO Akira

  Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Young Scientists (B), Kobe University, 01 Apr. 2017 - 31 Mar. 2019

  In antitumor immunity, T cells play a central role to eliminate cancer cells. T cells exhaust by chronic antigen-stimulation in cancer patients. The function of exhausted T cells decrease and can’t remove cancer specific antigen. At present, functional evaluation of T cells takes several days to obtain results. It is important to establish a system that can quickly assess the functional depression and exhaustion of T cells. Therefore, in this research project, we propose new method which detect IS formation of ex vivo T cells by using imaging cytometry. The study was conducted using T cells in human peripheral blood.